By Chief Executive Janet Morrison Late last month, the Community Pharmacy England Committee met to continue preparations for the upcoming CPCF negotiations and review long-term strategic priorities. We also welcomed new Committee members and were hugely grateful to all business owners who contributed evidence to us through recent polls and events. Key discussion areas included
Community Pharmacy England met in London on 19th and 20th November, with Committee members considering preparations for the next round of Community Pharmacy Contractual Framework (CPCF) negotiations, ongoing financial pressures, winter readiness and other important matters. Closing the sector’s longstanding funding gap and addressing operational pressures remain the central focus of the Committee. There has
As part of Community Pharmacy England’s commitment to working more closely with pharmacy owners – listening to them better, as well as engaging more regularly via events and other channels – we sought input from the sector ahead of the November 2025 Committee Meeting. Between October 20th to November 10th, the latest sector opinion poll
Community Pharmacy England met in London for a full Committee meeting on 19th and 20th November 2025. Committee discussions focused on the upcoming CPCF negotiations: financial pressures remain a very serious concern, with closing the funding gap still the Committee’s top priority. The Committee also considered the additional pressures that winter is expected bring to
The Department of Health and Social Care (DHSC) has today (28/11/2025) confirmed the following list of price concessions for November 2025: Please note: Community Pharmacy England has submitted price concession applications for a number of other medicines affected by pricing issues this month. We will issue further updates as soon as we hear back from the Department.
The Department of Health and Social Care (DHSC) has confirmed that sufficient stock of Cefalexin 125mg/5ml oral suspension sugar free and Cefalexin 250mg/5ml oral suspension sugar free is now available to meet normal demand. As a result the Serious Shortage Protocol (SSP), SSP077 Cefalexin 125mg/5ml oral suspension sugar free and SSP078 Cefalexin 250mg/5ml oral suspension
Following representations from Community Pharmacy England, the Department of Health and Social Care (DHSC) has re-determined that the following products will be granted special container status from 1 December 2025. Generic drug name (dm+d descriptor) Brand and/or manufacturer Pack Size Special container Salbutamol 2.5mg/2.5ml nebuliser liquid unit dose ampoules Teva UK Ltd 20 unit dose
The Department of Health and Social Care (DHSC) has today (27/11/2025) confirmed the following list of price concessions for November 2025: Drug Pack size Price concession Betamethasone 500microgram soluble tablets sugar free 100 £46.65 Cyclizine 50mg/1ml solution for injection ampoules 5 £3.80 Dexamethasone 500microgram tablets 28 £1.87 Fenofibrate micronised 67mg capsules 90 £8.69 Lansoprazole 30mg orodispersible tablets
MHRA Class 4 Medicines Defect Notification: Baclofen 10mg Tablets (Special Concept Development UK Limited) Drug alert number: EL(25)A/51 Date issued: 27 November 2025 Special Concept Development UK Limited has informed the MHRA that the Patient Information Leaflet (PIL) for the batches listed in this notification do not contain the correct safety information. DMRC reference number: DMRC –
From 1 December 2025, the use of the ‘FS’ prescriber endorsement has been extended to treatments used in the management of tuberculosis (TB) and latent TB infections, including the effects of TB and the adverse effects from TB treatment. Pharmacy teams should ensure that no prescription charge is levied for any items endorsed ‘FS’ by
